Literature DB >> 21981384

Influenza-associated bacterial pathogens in patients with 2009 influenza A (H1N1) infection: impact of community-associated methicillin-resistant Staphylococcus aureus in Queensland, Australia.

Y Hayashi1, V L Vaska, H Baba, G R Nimmo, L Davis, D L Paterson.   

Abstract

BACKGROUND: Secondary bacterial pneumonia due to community onset methicillin-resistant Staphylococcus aureus (MRSA) has become a highly publicised cause of influenza-associated death. There is a risk that case reports of fatal outcomes with post-influenza MRSA pneumonia may unduly influence antibiotic prescribing. AIMS: The aim of this study was to demonstrate the incidence of community-onset MRSA pneumonia in 2009 H1N1 influenza patients.
METHODS: The microbiology records of patients positive for influenza A (H1N1) in 2009 were reviewed for positive blood or respiratory tract cultures and urinary pneumococcal antigen results within a Queensland database. Patients with such positive results within 48 h of hospital admission and a positive H1N1 influenza result in the prior 6 weeks were included.
RESULTS: In 2009, 4491 laboratory-confirmed pandemic influenza A (H1N1) infections were detected. Fifty patients (1.1% of the H1N1 cohort) who were hospitalised with H1N1 and who had a bacterial respiratory tract pathogen were identified. Streptococcus pneumoniae (16 patients; 32%), Staphylococcus aureus (13 patients; 26%) and Haemophilus influenzae (9 patients; 18%) were the most commonly cultured organisms. Of the cohort of 4491 patients, MRSA was detected in only two patients, both of whom were admitted to intensive care units and survived after prolonged admissions.
CONCLUSIONS: Influenza-associated community-onset MRSA pneumonia was infrequently identified in the 2009 H1N1 season in Queensland, despite community-onset MRSA skin and soft tissue infections being very common. Although post-influenza MRSA pneumonia is of great concern, its influence on empiric-prescribing guidelines should take into account its incidence relative to other secondary bacterial pathogens.
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians.

Entities:  

Mesh:

Year:  2012        PMID: 21981384     DOI: 10.1111/j.1445-5994.2011.02602.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  4 in total

1.  Hapivirins and diprovirins: novel θ-defensin analogs with potent activity against influenza A virus.

Authors:  Mona Doss; Piotr Ruchala; Tesfaldet Tecle; Donald Gantz; Anamika Verma; Alex Hartshorn; Erika C Crouch; Hai Luong; Ewa D Micewicz; Robert I Lehrer; Kevan L Hartshorn
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

2.  Recent advances in the diagnosis and treatment of influenza pneumonia.

Authors:  Lucia Marzoratti; Hernán A Iannella; Victoria Fernández Gómez; Sandra B Figueroa
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

3.  Community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia without evidence of antecedent viral upper respiratory infection.

Authors:  Cristina Moran Toro; Jack Janvier; Kunyan Zhang; Kevin Fonseca; Dan Gregson; Deirdre Church; Kevin Laupland; Harvey Rabin; Sameer Elsayed; John Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-05       Impact factor: 2.471

Review 4.  Dynamic Propagation and Impact of Pandemic Influenza A (2009 H1N1) in Children: A Detailed Review.

Authors:  Yashwant Kumar Ratre; Naveen Kumar Vishvakarma; L V K S Bhaskar; Henu Kumar Verma
Journal:  Curr Microbiol       Date:  2020-09-21       Impact factor: 2.343

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.